Biotech holds steady in Q4

Article Abstract:

The fourth quarter (4Q) survey for the year 2003 shows that the biotech prices hold steadily and there are encouraging signs that investment in biotechnology is picking up. Carl Feldbaum, president of the Biotechnology Industry Organization (Washington, DC, USA), attributes the improving shares valuations to the industry's terrific success at obtaining marketing approval from the US Food and Drug Administration (FDA).

Marketing procedures, Biological Product (except Diagnostic) Manufacturing, Executive changes & profiles, Molecular Biological Products, Officials and employees, Marketing, Surveys, Company marketing practices, United States. Food and Drug Administration, Biotechnology, Biotechnology Industry Organization, Feldbaum, Carl

---

Any diamonds in the diagnostic coal?

Article Abstract:

Clinical testing and medical technology (Medtech) companies are likely to turn out winners of investments as compared to stand-alone diagnostic makers or drug companies with diagnostics divisions. It is felt that by 2015, large healthcare companies would show an immense shift, with diagnostic companies becoming part of large medtech firms, unless large pharmas become more like medtechs.

HEALTH SERVICES, Health care industry

---

Celltech acquisition sends mixed messages

Article Abstract:

The UCB, a little-known Belgian drug company acquired UK's eldest biotech company, Celltech, for 1.53 billion pound sterling. UCB warns that independent European biotechnology firms may never be able to rival American giants, however, the deal could lead to similar cross-border mergers that may be needed to restructure the industry in Europe so that it can compete with global players.

United Kingdom, Acquisitions & mergers, Mergers, acquisitions and divestments, Company acquisition/merger, Global economy, Celltech

Similar abstracts:

• Abstracts: Why we can hold our heads high again. Markets after the election. Full order books may be deceptive
• Abstracts: Recipe for indigestion. Diet and the risk of cancer. Pills for fat fighting?
• Abstracts: P-cards travel different roads to the same efficiencies. Recruiting creativity
• Abstracts: Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Recurrent gain of chromosomes 17q and 12 in cultured human embryonic stem cells
• Abstracts: Integrative model of the response of yeast to osmotic shock. Principles of transcriptional control in the metabolic network of Saccharomyces cerevisiae

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.